| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
2,648 |
2,282 |
$904K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,889 |
4,190 |
$250K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
3,766 |
3,421 |
$186K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
4,234 |
3,665 |
$65K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
949 |
744 |
$64K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
679 |
614 |
$63K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
231 |
212 |
$21K |
| 87486 |
|
331 |
291 |
$15K |
| 87581 |
|
331 |
291 |
$15K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
323 |
293 |
$11K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
393 |
353 |
$9K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
29 |
22 |
$7K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
563 |
386 |
$5K |
| 99000 |
|
200 |
193 |
$5K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
16 |
16 |
$2K |
| 94762 |
|
73 |
64 |
$2K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
16 |
16 |
$1K |
| 87400 |
|
89 |
79 |
$722.85 |
| 81003 |
|
306 |
273 |
$655.09 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
22 |
21 |
$430.89 |
| 87081 |
|
73 |
68 |
$411.80 |
| 94760 |
|
132 |
124 |
$402.86 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
13 |
12 |
$330.65 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
13 |
13 |
$325.00 |
| 96127 |
|
41 |
39 |
$248.48 |
| 81025 |
|
48 |
46 |
$243.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
16 |
12 |
$232.00 |
| 92587 |
|
18 |
17 |
$210.29 |
| 81002 |
|
62 |
61 |
$156.68 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
32 |
30 |
$19.53 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
28 |
25 |
$19.31 |